Literature DB >> 30923093

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors.

Anaïs Roeser1, Fleur Cohen-Aubart2, Paul Breillat1, Makoto Miyara3, Jean-François Emile4, Frédéric Charlotte5, Jean Donadieu6, Zahir Amoura1, Julien Haroche1.   

Abstract

Entities:  

Year:  2019        PMID： 30923093      PMCID： PMC6821627          DOI： 10.3324/haematol.2018.214007

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  19 in total

1.  Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.

Authors:  Jean-François Emile; Eli L Diamond; Zofia Hélias-Rodzewicz; Fleur Cohen-Aubart; Frédéric Charlotte; David M Hyman; Eunhee Kim; Raajit Rampal; Minal Patel; Chezi Ganzel; Shlomzion Aumann; Gladwys Faucher; Catherine Le Gall; Karen Leroy; Magali Colombat; Jean-Emmanuel Kahn; Salim Trad; Philippe Nizard; Jean Donadieu; Valérie Taly; Zahir Amoura; Omar Abdel-Wahab; Julien Haroche
Journal:  Blood       Date:  2014-08-22       Impact factor: 22.113

2.  The importance of considering monogenic causes of autoimmunity: A somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosus.

Authors:  Robert J Ragotte; Anita Dhanrajani; Julian Pleydell-Pearce; Kate L Del Bel; Maja Tarailo-Graovac; Clara van Karnebeek; Jefferson Terry; Christof Senger; Margaret L McKinnon; Michael Seear; Julie S Prendiville; Lori B Tucker; Kristin Houghton; David A Cabral; Jaime Guzman; Ross E Petty; Kelly L Brown; Jenny Tekano; John Wu; Kimberly A Morishita; Stuart E Turvey
Journal:  Clin Immunol       Date:  2016-12-31       Impact factor: 3.969

3.  Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial.

Authors:  Davide Gianfreda; Maria Nicastro; Maricla Galetti; Federico Alberici; Domenico Corradi; Gabriella Becchi; Giorgio Baldari; Massimo De Filippo; Stefania Ferretti; Gabriella Moroni; Rosario Foti; Marcella Di Gangi; Guido Jeannin; Raphael Saffroy; Jean-François Emile; Carlo Buzio; Augusto Vaglio
Journal:  Blood       Date:  2015-06-03       Impact factor: 22.113

4.  Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab.

Authors:  Lorenzo Dagna; Angelo Corti; Silvia Langheim; Barbara Guglielmi; Francesco De Cobelli; Claudio Doglioni; Gabriele Fragasso; Maria Grazia Sabbadini; Marina Ferrarini
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

5.  Pulmonary Langerhans Histiocytosis: an uncommon cause of interstitial pneumonia in a patient with Sjögren syndrome.

Authors:  Andrés González García; José Luis Callejas Rubio; Raquel Ríos Fernández; Norberto Ortego Centeno
Journal:  Clin Rheumatol       Date:  2015-04-19       Impact factor: 2.980

6.  Prevalence of autoantibodies in the course of Gaucher disease type 1: A multicenter study comparing Gaucher disease patients to healthy subjects.

Authors:  Christine Serratrice; Nesma Bensalah; Guillaume Penaranda; Nathalie Bardin; Nadia Belmatoug; Agathe Masseau; Christian Rose; Olivier Lidove; Fabrice Camou; François Maillot; Vanessa Leguy; Nadine Magy-Bertrand; Isabelle Marie; Patrick Cherin; Monia Bengherbia; Sebastian Carballo; José Boucraut; Jacques Serratrice; Marc Berger; Denis Verrot
Journal:  Joint Bone Spine       Date:  2016-12-26       Impact factor: 4.929

7.  Inhibition of the mTORC pathway in the antiphospholipid syndrome.

Authors:  Guillaume Canaud; Frank Bienaimé; Fanny Tabarin; Guillaume Bataillon; Danielle Seilhean; Laure-Hélène Noël; Marie-Agnès Dragon-Durey; Renaud Snanoudj; Gérard Friedlander; Lise Halbwachs-Mecarelli; Christophe Legendre; Fabiola Terzi
Journal:  N Engl J Med       Date:  2014-07-24       Impact factor: 91.245

8.  Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα.

Authors:  Jen C Wang; Hemant Sindhu; Chi Chen; Ajay Kundra; Muhammad I Kafeel; Ching Wong; Stephen Lichter
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

9.  Membrane-bound Fas ligand only is essential for Fas-induced apoptosis.

Authors:  Lorraine A O' Reilly; Lin Tai; Lily Lee; Elizabeth A Kruse; Stephanie Grabow; W Douglas Fairlie; Nicole M Haynes; David M Tarlinton; Jian-Guo Zhang; Gabrielle T Belz; Mark J Smyth; Philippe Bouillet; Lorraine Robb; Andreas Strasser
Journal:  Nature       Date:  2009-10-01       Impact factor: 49.962

10.  Erdheim-Chester Disease as a Mimic of IgG4-Related Disease: A Case Report and a Review of a Single-Center Cohort.

Authors:  Davide Gianfreda; Claudio Musetti; Maria Nicastro; Federica Maritati; Rocco Cobelli; Domenico Corradi; Augusto Vaglio
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889
View more
  5 in total

Review 1.  Erdheim-Chester disease: a rapidly evolving disease model.

Authors:  Francesco Pegoraro; Matthias Papo; Valerio Maniscalco; Frédéric Charlotte; Julien Haroche; Augusto Vaglio
Journal:  Leukemia       Date:  2020-06-26       Impact factor: 11.528

Review 2.  Erdheim-Chester Disease: a Concise Review.

Authors:  Matthias Papo; Jean-François Emile; Thiago Trovati Maciel; Pierre Bay; Alistair Baber; Olivier Hermine; Zahir Amoura; Julien Haroche
Journal:  Curr Rheumatol Rep       Date:  2019-12-05       Impact factor: 4.592

Review 3.  Histiocytosis.

Authors:  Jean-François Emile; Fleur Cohen-Aubart; Matthew Collin; Sylvie Fraitag; Ahmed Idbaih; Omar Abdel-Wahab; Barrett J Rollins; Jean Donadieu; Julien Haroche
Journal:  Lancet       Date:  2021-04-23       Impact factor: 202.731

4.  Profound systemic alteration of the immune phenotype and an immunoglobulin switch in Erdheim-Chester disease in 78 patients from a single center.

Authors:  Fleur Cohen Aubart; Lucie Poupel; Flora Saint-Charles; Frederic Charlotte; Youssef Arsafi; Eric Frisdal; Damien Roos-Weil; Jean-Francois Emile; Zahir Amoura; Maryse Guerin; Philippe Lesnik; Julien Haroche; Wilfried Le Goff
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

5.  Immune Thrombocytopenia Revealing Enriched IgG-4 Peri-Renal Rosai-Dorfman Disease Successfully Treated with Rituximab: A Case Report and Literature Review.

Authors:  Jerome Razanamahery; Sebastien Humbert; Jean-Francois Emile; Fleur Cohen-Aubart; Jean Fontan; Philippe Maksud; Sylvain Audia; Julien Haroche
Journal:  Front Med (Lausanne)       Date:  2021-06-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.